OncoMatch/Clinical Trials/NCT06311214
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Is NCT06311214 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Sacituzumab Govitecan and Trastuzumab Deruxtecan for advanced malignant solid neoplasm.
Treatment: Enfortumab Vedotin · Sacituzumab Govitecan · Trastuzumab Deruxtecan — This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works in treating patients with solid tumor cancers that have high expression of the Trop-2, nectin-4, or HER2 proteins and that may have spread from where they first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or to other places in the body (metastatic). Precision medicine is a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, or treat disease in a way that is tailored to the patient. ADCs such as sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan are monoclonal antibodies attached to biologically active drugs and are a form of targeted therapy. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab attaches to a protein called Trop-2 on the surface of tumor cells and delivers govitecan to kill them. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. Trastuzumab deruxtecan is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Personalized treatment with sacituzumab govitecan, enfortumab vedotin, or trastuzumab deruxtecan may be an effective treatment option for patients with advanced or metastatic solid tumors that screen positive for high expression of Trop-2, nectin-4, or HER2, respectively.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: TACSTD2 high protein expression (IHC 2+ or 3+) AND RNA overexpression (IHC 2+ or 3+ AND RNA overexpression)
Patient must have high Trop-2 protein expression (IHC 2+ or 3+) as determined by the MD Anderson Cancer Center Clinical Laboratory Improvement Amendments IHC assay; must also have RNA overexpression
Required: NECTIN4 high protein expression (IHC 2+ or 3+) (IHC 2+ or 3+)
Patient must have high Nectin-4 protein expression (IHC 2+ or 3+) as determined by the MD Anderson Cancer Center Clinical Laboratory Improvement Amendments IHC assay
Required: HER2 (ERBB2) high protein expression (IHC 2+ or 3+) AND RNA overexpression (IHC 2+ or 3+ AND RNA overexpression)
Patient must have HER2 protein expression (IHC 2+ or 3+) as determined by the MD Anderson Cancer Center (MDACC) IHC assay; must also have RNA overexpression
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: topoisomerase I inhibitor
Prior topoisomerase 1 inhibitor treatment
Cannot have received: Trop-2-targeting antibody-drug conjugate
Prior treatment with a Trop-2-targeting ADC
Cannot have received: ADC with vedotin payload
Prior treatment with an ADC with vedotin payload
Lab requirements
Blood counts
Hemoglobin > 9.0 g/dL; leukocytes ≥ 3000/mL; ANC ≥ 1,500/mL; platelets ≥ 100,000/mL; albumin ≥ 3 g/dL; no history of transfusion dependence; no persistent bone marrow suppression
Kidney function
Creatinine ≤ institutional ULN OR GFR ≥ 60 mL/min/1.73 m^2 (no lower than 30 mL/min/1.73 m^2 if data supports safe use)
Liver function
Total bilirubin ≤ 1.5 institutional ULN (Gilbert syndrome allowed if ≤ 3 × ULN); AST/ALT ≤ 2.5 × ULN (up to 5 × ULN with liver metastases allowed for treatment cohorts)
Cardiac function
LVEF ≥50% within 28 days before enrollment; NYHA class 2B or better
No history of transfusion dependence; no history of persistent bone marrow suppression (ANC ≥ 1,500/mL and platelets ≥ 100,000/mL not attributable to active therapy); albumin ≥ 3 g/dL; Total bilirubin ≤ 1.5 institutional ULN (Gilbert syndrome allowed if ≤ 3 × ULN); AST/ALT ≤ 2.5 × ULN (up to 5 × ULN with liver metastases allowed for treatment cohorts); Creatinine ≤ institutional ULN OR GFR ≥ 60 mL/min/1.73 m^2 (no lower than 30 mL/min/1.73 m^2 if data supports safe use); LVEF ≥50% within 28 days before enrollment; NYHA class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- UC San Diego Health System - Encinitas · Encinitas, California
- City of Hope at Irvine Lennar · Irvine, California
- UC San Diego Moores Cancer Center · La Jolla, California
- UC San Diego Medical Center - Hillcrest · San Diego, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify